Jaguar Health Provides Update Regarding Special Stock DividendDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's CrofelemerCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027 NDA filing for MVID
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu DhabiCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027A recent Rareatives article shares the story of a young child living with MVID, highlighting the importance of family perspectives, supportive communication, and collaboration with clinicians in addressing rare intestinal diseases
Jaguar Health Announces a Special Stock DividendDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology MeetingCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027
Jaguar Health Receives Fee Waivers from FDACompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027
Jaguar Health, Inc. Announces Reverse Stock SplitReverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026
